Clustering Based on Laboratory Data in Patients With Heart Failure Admitted to the Intensive Care Unit.

Background: Heart failure (HF) is a common condition that imposes a significant burden on healthcare systems. We aimed to identify subgroups of patients with heart failure admitted to the ICU using routinely measured laboratory biomarkers.

Methods: A large dataset (N = 1176) of patients with heart failure admitted to the ICU at the Beth Israel Deaconess Medical Center in Boston, USA, between June 1, 2001, and October 31, 2012, was analyzed.

Hypofractionated versus standard chemoradiotherapy in the definitive treatment of uterine cervix cancer: interim results of a randomized controlled clinical trial.

Purpose: Concurrent chemoradiation has been the mainstay of treatment for cervix cancer. We aimed to evaluate the non-inferiority of hypofractionated chemoradiation.

Methods: This study was designed as a phase 2, 1:1 randomized, investigator-blinded, controlled, non-inferiority trial and we report the interim results after 50% accrual.

Prognostic Clinical Phenotypes of Patients with Acute Decompensated Heart Failure.

Introduction: Acute decompensated heart failure (AHF) is a clinical syndrome with a poor prognosis.

Aim: This study was conducted to identify clusters of inpatients with acute decompensated heart failure that shared similarities in their clinical features.

Methods: We analyzed data from a cohort of patients with acute decompensated heart failure hospitalized between February 2013 and January 2017 in a Department of Cardiology.

Evaluating the safety and effectiveness of PegaGen (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study.

Purpose: Phase IV clinical trials are required to evaluate the real-world safety and effectiveness of drugs. This study aimed to evaluate the safety and effectiveness of once-per-cycle administration of PegaGen (pegfilgrastim, CinnaGen, Iran) in cancer patients.

Methods: In this open-label, multicenter, prospective, real-world, post-marketing surveillance study, patients with any type of cancer receiving chemotherapy regimens with a high risk of febrile neutropenia (FN) were included if they were prescribed pegfilgrastim for FN prophylaxis.

Prevalence and main determinants of early post-traumatic thromboembolism in patients requiring ICU admission.

Background: Post-traumatic thromboembolism (PE) is now a common challenging particularly in critically ill patients referred to emergency wards. We aimed to identify main factors associated with PE within 72 h of admission after trauma among patients referred to emergency ward.

Methods: In this retrospective study, the database records of 240 patients, with the primary diagnosis of trauma requiring ICU admission and with a final diagnosis of pulmonary embolism, were reviewed.

Assessment of patient safety culture among personnel in the hospitals associated with Islamic Azad University in Tehran in 2013.

Background: Patient safety is an essential element in the quality of healthcare, and a clear knowledge of its culture in healthcare organizations will lead to both improved healthcare and patient safety. The aim of this study was to assess the patient safety culture at Islamic Azad University hospitals in Tehran, Iran, in 2013.

Methods: This cross-sectional study was conducted on clinical and diagnostic staff in all Islamic Azad University hospitals in Tehran in June 2013.

Comparative efficacies of contact lens disinfecting solutions against Pseudomonas aeruginosa.

Purpose: The aim of the present study was to evaluate the disinfection properties of multipurpose contact lens disinfection solutions, based on the International Organization for Standardization (ISO) 14729 guidelines.

Methods: Three lots of each of six multi-purpose solutions were tested as follows: Renu MultiPlus, Solo Care Aqua, All-Clean Soft, Contact All-in one Advanced, Hippia, Ginza multi-purpose solution and 0.9% normal saline solution were inoculated with the standard strain of Pseudomonas aeruginosa (ATCC 9027).

High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications.

As a means to manage cardiac conditions, we determined the effects of high-dose intravenous (IV) deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours (maximum 5 g) for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment.